ARTV Company Profile and Key Details

Short-term trend indicators are mixed aligned (SMA20 27.46%, SMA50 22.05%, SMA200 68.67%). The stock’s 14-day RSI is 70.9 (overbought), while the ATR of 0.39 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -25.95% below its high and over 270.75% above its low. Average 10-day trading volume of 872.25 thousand shares is significantly above the 3-month average of 486.56 thousand, indicating heightened recent market interest.

Artiva Biotherapeutics, Inc. has 48.59 million shares outstanding. The public float is 6.00 million shares, elevated short interest at 3.02% of float. This equals 1.03 million shares. The short ratio is 1.59 days. Institutional investors hold 97.58% of the float. Insiders own 24.05%. RA CAPITAL MANAGEMENT, L.P. holds 16.76 million shares, venBio Global Strategic Fund III, L.P. has 1.94 million shares and GC Corp. has 1.61 million shares. Over the past six months, insider transactions show net buying. They sold 53.04 thousand shares across 5 transactions.

Artiva Biotherapeutics, Inc. generated EPS of -$3.25 over the past year. Five-year average earnings growth is -64.01%. Wall Street analysts project EPS growth of 24.02% annually over the next five years. Analyst sentiment is bullish. Analyst rating data shows there are 3 Strong Buy ratings, 7 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $41.00 to $15.00. The high target offers 360.16% upside. The low target suggests 68.35% downside. The mean target is $28.90. This offers 224.35% upside. Artiva Biotherapeutics, Inc. earnings surprise history is a mixed track record. The quarter that ended May 08, 2026, missed forecasts by 7.95%. The prior quarter beat by -3.45%. Over the last six quarters, Apple has recorded several small beats. These include -7.04% in March 25, 2025.

Artiva Biotherapeutics, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $0.64. This means the shares are trading above this model’s fair value.

Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) closed at $10.15 USD, gaining $1.24 (13.97%) from the previous close of $8.91. The stock is currently mid-range between its 52-week high and low $1.47 and $14.53. With a market capitalization of about $251.00 million, Artiva Biotherapeutics, Inc. is classified as a micro-cap and shows higher-than-market volatility (beta ~2.40). Key stats such as the average daily volume over the past year has been around 487.16 thousand shares, in line with its 52-week average. Headquartered in San Diego, CA, Artiva Biotherapeutics, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Fred Aslan, the company employs approximately 96 people and listed since July 19, 2024. Artiva Biotherapeutics, Inc. is a clinical-stage biotechnology firm specializing in the development of natural killer (NK) cell-based treatments for individuals afflicted with autoimmune disorders and various forms of cancer.

Artiva Biotherapeutics, Inc. trades at a P/E ratio of -2.53, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 2.51 suggesting the stock is closer to book value. The P/FCF stands at -2.75, also above market averages.

Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) shares are flat 7.69% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Artiva Biotherapeutics, Inc. trading at a premium to the broader market with a P/E of -2.53. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $24.90, suggesting 179.46% upside. Our AI forecast model points to short-term weakness (-15.26% over two weeks), a medium-term rise (229.85% over three months), and a longer-term gain (149.83% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that Artiva Biotherapeutics, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -15.26%, with price expected at $7.55 by June 30, 2026, within a range of $6.34 to $8.76 3-Month Outlook: Projected rise of 229.85%, reaching $29.39 by September 14, 2026, with a range of $29.12 to $29.70. 1-Year Outlook: Projected gain of 149.83%, with price at $22.26 by June 16, 2027, within a range of $21.94 to $22.55.